SOLVE-TAVI试验:新一代自膨胀瓣膜与球囊扩张瓣膜在经导管主动脉瓣植入术中的随机 comparison
SOLVE-TAVI是一项多中心、开放标签、2×2析因设计的随机试验,纳入447例接受经股动脉TAVI的主动脉瓣狭窄患者,比较新一代自膨胀瓣膜(Evolut R)与球囊扩张瓣膜(Sapien 3)。主要复合疗效终点(30天全因死亡、卒中、中/重度瓣周漏及永久起搏器植入)在两组间达到等效性(SEV 28.4% vs BEV 26.1%,率差-2.39,90%CI -9.45至4.66,P等效=0.04),支持两类瓣膜的安全应用。
要点
- 30天主要复合终点SEV与BEV达到等效(28.4% vs 26.1%)。
- 卒中发生率BEV组高于SEV组(4.7% vs 0.5%),等效性P=0.003。
- 永久起搏器植入率两组相近(23.0% vs 19.2%),等效性P=0.06。
核心结论
- 在经股动脉TAVI的主动脉瓣狭窄患者中,新一代自膨胀瓣膜与球囊扩张瓣膜在主要瓣膜相关疗效终点上等效。
研究设计与样本
- SOLVE-TAVI为多中心、开放标签、2×2析因随机试验,纳入447例接受经股动脉TAVI的主动脉瓣狭窄患者,比较SEV(Evolut R)与BEV(Sapien 3)。
主要发现
- 30天主要复合终点发生率SEV组28.4%、BEV组26.1%,率差-2.39(90%CI -9.45至4.66),P等效=0.04。
- 全因死亡率SEV组3.2%、BEV组2.3%,率差-0.93(90%CI -4.78至2.92),P等效<0.001。
- 卒中发生率SEV组0.5%、BEV组4.7%,率差4.20(90%CI 0.12至8.27),P等效=0.003。
- 中/重度瓣周漏发生率SEV组3.4%、BEV组1.5%,率差-1.89(90%CI -5.86至2.08),P等效=0.0001。
- 永久起搏器植入率SEV组23.0%、BEV组19.2%,率差-3.85(90%CI -10.41至2.72),P等效=0.06。
关键数值与推荐
- 主要复合终点为30天全因死亡、卒中、中/重度人工瓣膜反流及永久起搏器植入,等效界值10%,显著性水平0.05。
临床怎么用
- 新一代SEV与BEV均可安全用于多数主动脉瓣狭窄患者的经股动脉TAVI,具体瓣膜选择可基于个体瓣膜解剖特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Transcatheter aortic valve implantation (TAVI) has emerged as established treatment option in patients with symptomatic aortic stenosis. Technical developments in valve design have addressed previous limitations such as suboptimal deployment, conduction disturbances, and paravalvular leakage. However, there are only limited data available for the comparison of newer generation self-expandable valve (SEV) and balloon-expandable valve (BEV). METHODS AND RESULTS: SOLVE-TAVI is a multicentre, open-label, 2 × 2 factorial, randomized trial of 447 patients with aortic stenosis undergoing transfemoral TAVI comparing SEV (Evolut R, Medtronic Inc., Minneapolis, MN, USA) with BEV (Sapien 3, Edwards Lifesciences, Irvine, CA, USA). The primary efficacy composite endpoint of all-cause mortality, stroke, moderate/severe prosthetic valve regurgitation, and permanent pacemaker implantation at 30 days was powered for equivalence (equivalence margin 10% with significance level 0.05). The primary composite endpoint occurred in 28.4% of SEV patients and 26.1% of BEV patients meeting the prespecified criteria of equivalence [rate difference -2.39 (90% confidence interval, CI -9.45 to 4.66); Pequivalence = 0.04]. Event rates for the individual components were as follows: all-cause mortality 3.2% vs. 2.3% [rate difference -0.93 (90% CI -4.78 to 2.92); Pequivalence < 0.001], stroke 0.5% vs. 4.7% [rate difference 4.20 (90% CI 0.12 to 8.27); Pequivalence = 0.003], moderate/severe paravalvular leak 3.4% vs. 1.5% [rate difference -1.89 (90% CI -5.86 to 2.08); Pequivalence = 0.0001], and permanent pacemaker implantation 23.0% vs. 19.2% [rate difference -3.85 (90% CI -10.41 to 2.72) in SEV vs. BEV patients; Pequivalence = 0.06]. CONCLUSION: In patients with aortic stenosis undergoing transfemoral TAVI, newer generation SEV and BEV are equivalent for the primary valve-related efficacy endpoint. These findings support the safe application of these newer generation percutaneous valves in the majority of patients with some specific preferences based on individual valve anatomy.
引用
- Thiele H, Kurz T, Feistritzer HJ, et al. Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. Eur Heart J. 2020. PMID: 32049283. doi:10.1093/eurheartj/ehaa036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。